First Healthy Twins Born After Aneuploid Embryo Transfer Challenges IVF Assumptions

Spread the Message

Read Time:2 Minute, 48 Second

In an unprecedented medical case, researchers have reported the birth of healthy twin girls following the transfer of embryos labeled as aneuploid, meaning they carried abnormal chromosome numbers, during in vitro fertilization (IVF) with pre-implantation genetic testing for aneuploidy (PGT-A). This rare case was documented recently at a time when such transfers typically do not lead to chromosomally normal live births, marking a potential paradigm shift in reproductive medicine.

A couple, consisting of a 42-year-old woman and her 49-year-old partner, underwent IVF with next-generation sequencing-based PGT-A following the tragic death of their daughter. After thorough genetic counseling and informed consent, they chose to transfer three uniformly aneuploid female embryos along with one normal (euploid) male embryo. Contrary to expectations, the woman conceived a dichorionic, diamniotic twin pregnancy and delivered vaginally at 36 weeks following premature rupture of membranes.

Postnatal chromosomal microarray testing confirmed that both newborns had normal female karyotypes—meaning they were chromosomally healthy despite the embryos’ initial aneuploid classification. Further genetic analysis revealed the twins were dizygotic (non-identical), indicating that both originated from different embryos. Now approaching seven years old, the twins remain healthy with no developmental concerns reported.

This case highlights important limitations in current embryo screening technologies. Research shows that over 98% of transfers involving uniformly aneuploid embryos fail to result in chromosomally normal live births, making this outcome exceptionally rare. The researchers speculate that mechanisms such as embryo self-correction or diagnostic errors in PGT-A might explain these unexpected results. They emphasize the need for larger, prospective studies to assess the frequency of euploid live births after aneuploid embryo transfer as well as the long-term health outcomes of such children.

From a reproductive medicine standpoint, this discovery challenges the prevailing view that non-euploid embryos are invariably non-viable. PGT-A is widely regarded as a valuable tool for selecting embryos with the best chance of successful implantation and healthy birth. However, rare live births following aneuploid embryo transfers suggest cautious consideration before discarding embryos classified as abnormal. The case has prompted the initiation of the Transfer of Aneuploid and Mosaic Embryo (TAME) study, aimed at understanding underlying biological mechanisms and improving clinical decision-making.

Medical experts not involved in the study noted that while this case is incredible, it should not yet change clinical guidelines or patient counseling, given the rarity and uncertain reproducibility of such outcomes. They stress that PGT-A remains a cornerstone technology for enhancing IVF success rates, but acknowledge the need to refine and validate testing to minimize false positives and support individualized treatment plans.

For patients and health-conscious readers, the practical implication is that IVF and embryo selection, though highly advanced, remain complex and sometimes unpredictable. Couples undergoing reproductive treatment should engage in detailed discussions with fertility specialists regarding the benefits, limitations, and uncertainties associated with genetic screening of embryos.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References: